Rory Justo, MD
Internal Medicine · Kimball, TNNPI 1639160203
Payments from drug & device makers
Across 143 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$719
- Lilly USA, LLC$284
- Bayer$203
- Pfizer$174
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$158
- AbbVie$141
- plus $844 from 18 others
What the payments were for
- Food & beverage$2,524100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $719 |
| Lilly USA, LLC | 15 | $284 |
| Bayer | 10 | $203 |
| Pfizer | 11 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $158 |
| AbbVie(2 entities) | 7 | $141 |
| AstraZeneca | 8 | $111 |
| Dexcom, Inc. | 7 | $102 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| Abbott | 4 | $78 |
| GSK | 4 | $74 |
| Esperion Therapeutics, Inc. | 4 | $73 |
| Amgen | 4 | $65 |
| Exact Sciences | 4 | $62 |
| Astellas Pharma US Inc | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,524 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $84,160 |
| OzempicSemaglutide | 62 | $77,309 |
| JardianceEmpagliflozin | 52 | $54,517 |
| MounjaroTirzepatide | 29 | $44,495 |
| XareltoRivaroxaban | 42 | $29,307 |
| TrulicityDulaglutide | 22 | $22,370 |
| JanuviaSitagliptin Phosphate | 22 | $20,482 |
| FarxigaDapagliflozin Propanediol | 28 | $20,059 |
| LinzessLinaclotide | 16 | $16,480 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $15,833 |
| VascepaIcosapent Ethyl | 22 | $11,564 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $9,998 |
| TradjentaLinagliptin | 17 | $8,763 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $8,171 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $6,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $174 | $84,16099 claims |
| Novo NordiskOzempic | $719 | $77,30962 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $66,86551 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $15 | $36,88349 claims |
| Johnson & JohnsonXarelto | $23 | $29,30742 claims |
| AstraZenecaFarxiga, Symbicort | $111 | $22,78540 claims |
| AbbVieLinzess | $141 | $16,48016 claims |
| GSKTrelegy Ellipta | $74 | $15,83325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Kimball
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.